Sacubitril & Valsartan Tablets, manufactured by Kureasia Pharma, are an advanced combination therapy formulated to provide comprehensive management of chronic heart failure. This innovative dual-acting medicine combines the benefits of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan) to enhance cardiac performance and reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF).
Sacubitril acts as a prodrug that converts into its active metabolite, which inhibits the enzyme neprilysin responsible for breaking down natriuretic peptides. This inhibition increases levels of these beneficial peptides, promoting vasodilation, sodium excretion, and reduced fluid retention, ultimately decreasing the strain on the heart. Valsartan complements this action by blocking the angiotensin II type-1 (AT₁) receptor, thereby preventing vasoconstriction and the secretion of aldosterone. The synergistic combination of these mechanisms provides superior efficacy in improving hemodynamic stability and cardiac output while controlling blood pressure and reducing progression of heart failure.
Kureasia Pharma’s Sacubitril & Valsartan Tablets are formulated with precision and manufactured under strict WHO-GMP certified conditions to ensure consistent quality, purity, and stability. Each batch undergoes rigorous in-process and finished product testing for potency, uniformity, dissolution, and bioavailability. The product is available in multiple strengths such as 24/26 mg, 49/51 mg, and 97/103 mg, providing flexibility in dosage titration based on clinical response and patient tolerance.
This formulation is indicated for adults with chronic heart failure to reduce cardiovascular mortality and hospitalization risks. It can also be used in pediatric patients aged one year and above with systemic left ventricular systolic dysfunction, as recommended by clinical guidelines. By improving cardiac efficiency and preventing neurohormonal overactivation, Sacubitril & Valsartan significantly enhances patient outcomes and quality of life.
The tablets are film-coated, easy to swallow, and designed for twice-daily administration. They should not be co-administered with ACE inhibitors or used in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. Common side effects may include hypotension, hyperkalemia, dizziness, and renal function changes, which are generally mild and manageable under medical supervision.
Kureasia Pharma ensures that Sacubitril & Valsartan Tablets meet global regulatory and pharmacopeial standards. Each product is developed with a focus on therapeutic reliability, patient safety, and clinical effectiveness. The tablets are packed in moisture-resistant blister or bottle packs to maintain stability and shelf life. With a commitment to innovation and quality, Kureasia Pharma aims to make advanced cardiovascular care accessible and affordable through its high-performance pharmaceutical formulations.
Sacubitril & Valsartan Tablets by Kureasia Pharma represent a breakthrough approach in heart failure therapy—offering dual neurohormonal modulation, optimized heart protection, and improved long-term outcomes for patients worldwide